Search research articles
Contact Us
Filters
Showing results (21-30 of 49) with videos related to
Page
of 5
Sort By:
Journal of Neurochemistry
|
August 11, 2006
Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations
Eva De Lago, Sofia B Gustafsson, Javier Fernández-Ruiz, et al.
International Journal of Molecular Sciences
|
August 27, 2021
Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis
Loreto Martínez-González, Claudia Gonzalo-Consuegra, Marta Gómez-Almería, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology
|
March 31, 2015
Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders
Francisco Espejo-Porras, Fabiana Piscitelli, Roberta Verde, et al.
International Journal of Molecular Sciences
|
October 27, 2022
Discovery of Mitophagy Inhibitors with Therapeutic Potential in Different Familial Amyotrophic Lateral Sclerosis Mutations
Ines Maestro, Laura R de la Ballina, Gracia Porras, et al.
Brain Pathology (Zurich, Switzerland)
|
May 13, 2021
Inactivation of the CB<sub>2</sub> receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis
Carmen Rodríguez-Cueto, Marta Gómez-Almería, Laura García Toscano, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
July 12, 2005
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders
Eva de Lago, Javier Fernández-Ruiz, Silvia Ortega-Gutiérrez, et al.
Disease Models & Mechanisms
|
January 11, 2017
Upregulation of CB<sub>2</sub> receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis
María Fernández-Trapero, Francisco Espejo-Porras, Carmen Rodríguez-Cueto, et al.
Antioxidants (Basel, Switzerland)
|
September 28, 2024
Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia
Ignacio Silva-Llanes, Raquel Martín-Baquero, Alicia Berrojo-Armisen, et al.
Biochemical Pharmacology
|
August 5, 2018
Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1<sup>G93A</sup> transgenic mice, an experimental model of amyotrophic lateral sclerosis
Carmen Rodríguez-Cueto, Irene Santos-García, Laura García-Toscano, et al.
Multiple Sclerosis and Related Disorders
|
November 23, 2015
The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors
Miguel Moreno-Martet, Ana Feliú, Francisco Espejo-Porras, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 49) with videos related to
Sort By:
Page
of 5
Journal of Neurochemistry
|
August 11, 2006
Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations
Eva De Lago, Sofia B Gustafsson, Javier Fernández-Ruiz, et al.
International Journal of Molecular Sciences
|
August 27, 2021
Tideglusib, a Non-ATP Competitive Inhibitor of GSK-3β as a Drug Candidate for the Treatment of Amyotrophic Lateral Sclerosis
Loreto Martínez-González, Claudia Gonzalo-Consuegra, Marta Gómez-Almería, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology
|
March 31, 2015
Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders
Francisco Espejo-Porras, Fabiana Piscitelli, Roberta Verde, et al.
International Journal of Molecular Sciences
|
October 27, 2022
Discovery of Mitophagy Inhibitors with Therapeutic Potential in Different Familial Amyotrophic Lateral Sclerosis Mutations
Ines Maestro, Laura R de la Ballina, Gracia Porras, et al.
Brain Pathology (Zurich, Switzerland)
|
May 13, 2021
Inactivation of the CB<sub>2</sub> receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis
Carmen Rodríguez-Cueto, Marta Gómez-Almería, Laura García Toscano, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
July 12, 2005
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders
Eva de Lago, Javier Fernández-Ruiz, Silvia Ortega-Gutiérrez, et al.
Disease Models & Mechanisms
|
January 11, 2017
Upregulation of CB<sub>2</sub> receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis
María Fernández-Trapero, Francisco Espejo-Porras, Carmen Rodríguez-Cueto, et al.
Antioxidants (Basel, Switzerland)
|
September 28, 2024
Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia
Ignacio Silva-Llanes, Raquel Martín-Baquero, Alicia Berrojo-Armisen, et al.
Biochemical Pharmacology
|
August 5, 2018
Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1<sup>G93A</sup> transgenic mice, an experimental model of amyotrophic lateral sclerosis
Carmen Rodríguez-Cueto, Irene Santos-García, Laura García-Toscano, et al.
Multiple Sclerosis and Related Disorders
|
November 23, 2015
The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors
Miguel Moreno-Martet, Ana Feliú, Francisco Espejo-Porras, et al.
Page
of 5